New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
10:46 EDTWY, JOE, LPX, ADES, MTZ, DNR, WAT, RNA, TPH, ABBHigh option volume stocks: WY TPH RNA WAT DNR MTZ ADES LPX JOE ABB
News For WY;TPH;RNA;WAT;DNR;MTZ;ADES;LPX;JOE;ABB From The Last 14 Days
Check below for free stories on WY;TPH;RNA;WAT;DNR;MTZ;ADES;LPX;JOE;ABB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 11, 2014
18:08 EDTWATWaters initiated with a Hold at Stifel
Subscribe for More Information
16:46 EDTMTZMasTec sees FY14 adjusted EPS $1.55-$1.58, consensus $1.82
Subscribe for More Information
16:45 EDTMTZMasTec sees Q3 adjusted EPS approximately 56c, consensus 61c
Subscribe for More Information
16:43 EDTMTZMasTec CEO sees return to normalized level of wireless project revenue in FY15
Subscribe for More Information
16:39 EDTMTZMasTec reports Q2 adjusted EPS 40c, consensus 40c
Subscribe for More Information
16:07 EDTRNAProsensa to get additional funding from nonprofit CureDuchenne
Prosensa Holding announced that an affiliate of CureDuchenne, a U.S. national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy, or DMD, will provide Prosensa with up to EUR5M by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. The closing of EUR4.5M of the notes is contingent upon specified milestones in the advancement of drisapersen and the company's other exon skipping candidates in Prosensa's DMD portfolio. The funding arrangement will assist the company in progressing the second exon skipping candidate for the treatment of DMD, PRO044, by initiating a Phase II clinical extension study in Europe by the end of 2014 and a placebo-controlled trial in the U.S. in the first half of 2015, which may serve as one of two confirmatory studies to support a potential accelerated approval for drisapersen. It will also support re-dosing efforts for drisapersen clinical trial participants in North America and Europe and facilitate the drug's New Drug Application filing in the U.S. in 2014 along with the development of other Prosensa's other exon skipping compounds, PRO045 and PRO053.
15:27 EDTRNAWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
10:21 EDTADESAdvanced Emissions management to meet with Needham
Subscribe for More Information
10:19 EDTTPHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:10 EDTTPHTRI Pointe Homes resumed with a Buy at Citigroup
Subscribe for More Information
August 8, 2014
10:16 EDTJOEHigh option volume stocks
High option volume stocks: TKMR JOE HMSY TDC XOMA XPO VGK DKS BCOR DRTX
August 7, 2014
17:38 EDTJOESaint Joe Co. reports Q2 EPS 16c, one estimate 1c
Subscribe for More Information
11:20 EDTRNAProsensa management to meet with Roth Capital
Subscribe for More Information
11:18 EDTRNAProsensa management to meet with Oppenheimer
Subscribe for More Information
06:39 EDTTPHTRI Pointe Homes sees FY15 EPS $1.25-$1.40, consensus $1.28
06:38 EDTTPHTRI Pointe Homes to deliver 55% of 1,473 units in backlog during Q3
Subscribe for More Information
06:38 EDTTPHTRI Pointe Homes expects too deliver 2,000-2,100 homes
Subscribe for More Information
06:37 EDTTPHTRI Pointe Homes: Q3 to be negatively impacted by $35M-$40M in WRECO expenses
Subscribe for More Information
06:36 EDTTPHTRI Pointe Homes reports Q2 new home orders up to 190
Subscribe for More Information
06:36 EDTTPHTRI Pointe Homes reports Q2 EPS excluding WRECO expenses 20c, consensus 15c
Reports Q2 revenue $87.34M, consensus $75.4M
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use